Daniel O'Neil
Medical Oncology · Waterbury, CTNPI 1962764209
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $272 of the $311 with a category attached, or 87.5%. 5 manufacturers reported payments, led by AstraZeneca at 40.2% of the total. That places this record below the midpoint for medical oncology clinicians in CT, where the typical reported total is $3,212.
Across 9 payments — averaging $34.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$125
- Daiichi Sankyo Inc.$122
- Caris MPI, Inc.$37
- Seagen Inc.$15
- Gilead$12
Across 16 payments — averaging $27,038 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$433K
What the payments were for
- Food & beverage$27287%
- Education$3913%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $125 |
| Daiichi Sankyo Inc. | 5 | $122 |
| Caris MPI, Inc. | 1 | $37 |
| Seagen Inc. | 1 | $15 |
| Gilead | 1 | $12 |
How this compares
$311 in reported general payments places this provider in the 30th percentile of 79 medical oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 11 | $179,319 |
| EliquisApixaban | 12 | $7,313 |
| Exemestane | 28 | $2,758 |
| Anastrozole | 164 | $2,751 |
| Tamoxifen Citrate | 65 | $1,322 |
| Ondansetron OdtOndansetron | 14 | $399 |
| Prochlorperazine Maleate | 13 | $247 |
| Letrozole | 11 | $206 |
| LoperamideLoperamide Hcl | 11 | $102 |
| Gabapentin | 16 | $87 |
| Dexamethasone | 12 | $84 |
| Lorazepam | 11 | $28 |
| Alendronate Sodium | 14 | $10 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Waterbury
- Peter MarksNew Haven$578K
- Daniel PetrylakNew Haven$446K
- Mandar MuzumdarNew Haven$371K
- Barbara BurtnessNew Haven$297K
- Ian KropNew Haven$219K
- Joseph McLaughlinManchester$200K
- Francine FossNew Haven$193K
- William OhGreenwich$162K
- Anne ChiangNew Haven$158K
- Mario SznolNew Haven$157K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.